The first topic concerns the recent addition of financial consulting to Eutro's activities. We advise privately owned small to medium sized enterprises on how to get into the proper posture to raise money from the securities markets. Eutro is compensated in both cash and in stock of the clients' enterprise. 

The stock will be distributed pro rata to our stockholders. Particulars on each distribution will be provided to you. There are several such clients in the pipeline of which you can expect to receive your share of the common stock earned by Eutro. We feel it is proper to inform you that existing securities regulations impose a six month waiting period before Eutro can effect the distribution to you. Since we all are law abiding citizens, we will comply with the law and you may rest assured the stock will be distributed to you just as quickly as is legally possible.

The plan-of-action as per the document 'Premise' is: 

1. Acquire more distributors and customers.
2. Acquire certain diagnostic companies that will contribute additional products and greater distribution to our broad base.
  
New acquisitions are specified by: 
 
1. It has been established for a minimum of five years.
2. It has annual revenues of at least a million dollars consistently over the last several years.
3. It has products that we can use that will add to our product base.
4. It possesses a margin of profit that will contribute to the bottom line of Eutro.
  
The goal is to eventually provide one stop shop for commercial labs, hospitals and doctors offices. 

About six potential targets for acquisition exist that could contribute significantly to Eutro. However, distribution is key and a distributor has been contacted that may contribute with up to $2.8 million dollars if an acquisition is made. 

Including the planned acquisitions Eutro will have revenues of approximately $9 million dollars with a profit margin before tax of 12%. Industry average being 8-12%.

Mr Albert Shackelton and Mr. Daniel Birbilis rejoins the company. Mr. Birbilis will assume the position of Secretary/Treasurer. 

Mr. Shackelton and Mr. Birbilis will join Mr. William Herndon, President of Bio-Analytic, on the Executive Advisory Committee to assist and advice Floyd Wilkenson in expedition of Acquisitions and Contracts for New Products, as well as Marketing and New Product Development activities. 
 

This situation forces Eutro to obtain funds from the issuance of common stock according to Reg. D. 
 

Eutro Group Holding, Inc. is involved in providing capital to bring new products to market, technical assistance to develop marketing and sales opportunities and furnishes a strong management core, with over 70 years experience in securities, investment banking and management consulting. 

Eutro's newest endeavor is to assist companies to obtain the proper posture to raise capital necessary for these companies to become successful. In addition, Eutro acts as management and financial consultants. 

[...] 

Eutro Group Holding, Inc.'s businesses, directly and through its subsidiary, is centered on their core services: production, selling and distribution of a wide assortment of health products to a broad array of wellness products to consumers, and professional management advice. 

[...] 

Eutro was originally conceived as a holding company which would have as its primary activity the maximization of the value of its security portfolio. Its modus operandi was to have been proactive investment banking, meaning that it would actively seek to implement its investment concepts rather than simply wait for potential clients to approach it. While there may be a mega difference in size, the basic concept is similar to that of Berkshire Hathaway. Simply stated, Eutro will be compensated in three possible ways for the services it renders to its clients. First, is a cash payment to cover actual expenses and leave a profit. Second, is a block of the clients common shares. Third is the possibility of an ongoing relationship with the client as financial consultant/advisor.